MYCN amplification, 1p-loss and 17q gain are strongly associated with aggressive tumour and unfavourable outcome for the patient, whereas triploidy is associated with low stage neuroblastomas and a favourable outcome. This evidence concerns the gene MYCN and neuroblastoma.